Logo image of EYPT

EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Fundamental Analysis

USA - NASDAQ:EYPT - US30233G2093 - Common Stock

13.39 USD
+0.03 (+0.22%)
Last: 9/23/2025, 8:00:02 PM
13.39 USD
0 (0%)
After Hours: 9/23/2025, 8:00:02 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EYPT. EYPT was compared to 196 industry peers in the Pharmaceuticals industry. EYPT has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, EYPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EYPT has reported negative net income.
In the past year EYPT has reported a negative cash flow from operations.
EYPT had negative earnings in each of the past 5 years.
EYPT had negative operating cash flow in 4 of the past 5 years.
EYPT Yearly Net Income VS EBIT VS OCF VS FCFEYPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

The Return On Assets of EYPT (-58.24%) is worse than 63.78% of its industry peers.
Looking at the Return On Equity, with a value of -71.29%, EYPT is in line with its industry, outperforming 46.43% of the companies in the same industry.
Industry RankSector Rank
ROA -58.24%
ROE -71.29%
ROIC N/A
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
EYPT Yearly ROA, ROE, ROICEYPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 95.14%, EYPT belongs to the top of the industry, outperforming 96.94% of the companies in the same industry.
EYPT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for EYPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
EYPT Yearly Profit, Operating, Gross MarginsEYPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
EYPT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EYPT has been increased compared to 5 years ago.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EYPT Yearly Shares OutstandingEYPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EYPT Yearly Total Debt VS Total AssetsEYPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.52 indicates that EYPT is not in any danger for bankruptcy at the moment.
EYPT's Altman-Z score of 4.52 is fine compared to the rest of the industry. EYPT outperforms 77.55% of its industry peers.
There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.52
ROIC/WACCN/A
WACC9.82%
EYPT Yearly LT Debt VS Equity VS FCFEYPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

EYPT has a Current Ratio of 8.00. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.00, EYPT is doing good in the industry, outperforming 78.06% of the companies in the same industry.
A Quick Ratio of 7.91 indicates that EYPT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.91, EYPT is in the better half of the industry, outperforming 78.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8
Quick Ratio 7.91
EYPT Yearly Current Assets VS Current LiabilitesEYPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

EYPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.72%.
EYPT shows a small growth in Revenue. In the last year, the Revenue has grown by 2.99%.
EYPT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.26% yearly.
EPS 1Y (TTM)-49.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.55%
Revenue 1Y (TTM)2.99%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%-43.73%

3.2 Future

EYPT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.88% yearly.
Based on estimates for the next years, EYPT will show a very strong growth in Revenue. The Revenue will grow by 62.86% on average per year.
EPS Next Y-33.51%
EPS Next 2Y-16.79%
EPS Next 3Y-11.51%
EPS Next 5Y20.88%
Revenue Next Year-14.15%
Revenue Next 2Y-38.89%
Revenue Next 3Y27.49%
Revenue Next 5Y62.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EYPT Yearly Revenue VS EstimatesEYPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
EYPT Yearly EPS VS EstimatesEYPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYPT Price Earnings VS Forward Price EarningsEYPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EYPT Per share dataEYPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as EYPT's earnings are expected to decrease with -11.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.79%
EPS Next 3Y-11.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EYPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYEPOINT PHARMACEUTICALS INC

NASDAQ:EYPT (9/23/2025, 8:00:02 PM)

After market: 13.39 0 (0%)

13.39

+0.03 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners106.15%
Inst Owner Change-6.92%
Ins Owners3.52%
Ins Owner Change-0.02%
Market Cap922.97M
Analysts85.26
Price Target35.89 (168.04%)
Short Float %12.97%
Short Ratio11.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.89%
Min EPS beat(2)-4.55%
Max EPS beat(2)2.78%
EPS beat(4)2
Avg EPS beat(4)-5.51%
Min EPS beat(4)-25.16%
Max EPS beat(4)4.9%
EPS beat(8)4
Avg EPS beat(8)1.3%
EPS beat(12)6
Avg EPS beat(12)-18.77%
EPS beat(16)8
Avg EPS beat(16)-16.7%
Revenue beat(2)1
Avg Revenue beat(2)89.71%
Min Revenue beat(2)-21.1%
Max Revenue beat(2)200.52%
Revenue beat(4)3
Avg Revenue beat(4)46.06%
Min Revenue beat(4)-21.1%
Max Revenue beat(4)200.52%
Revenue beat(8)6
Avg Revenue beat(8)43.54%
Revenue beat(12)7
Avg Revenue beat(12)21.53%
Revenue beat(16)9
Avg Revenue beat(16)16.28%
PT rev (1m)9.37%
PT rev (3m)11.39%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-4.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.58%
Revenue NQ rev (1m)13.16%
Revenue NQ rev (3m)-33.53%
Revenue NY rev (1m)6.67%
Revenue NY rev (3m)-10.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.78
P/FCF N/A
P/OCF N/A
P/B 3.75
P/tB 3.75
EV/EBITDA N/A
EPS(TTM)-2.68
EYN/A
EPS(NY)-3.15
Fwd EYN/A
FCF(TTM)-2.82
FCFYN/A
OCF(TTM)-2.76
OCFYN/A
SpS0.75
BVpS3.57
TBVpS3.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.24%
ROE -71.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.14%
FCFM N/A
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.84%
Cap/Sales 6.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8
Quick Ratio 7.91
Altman-Z 4.52
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)367.17%
Cap/Depr(5y)224.18%
Cap/Sales(3y)7.38%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.55%
EPS Next Y-33.51%
EPS Next 2Y-16.79%
EPS Next 3Y-11.51%
EPS Next 5Y20.88%
Revenue 1Y (TTM)2.99%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%-43.73%
Revenue Next Year-14.15%
Revenue Next 2Y-38.89%
Revenue Next 3Y27.49%
Revenue Next 5Y62.86%
EBIT growth 1Y-91.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year118.73%
EBIT Next 3Y24.47%
EBIT Next 5YN/A
FCF growth 1Y-1744.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1418.02%
OCF growth 3YN/A
OCF growth 5YN/A